Today we have announced we are mobilizing the largest humanitarian relief effort in our company’s history to help the people of India fight the vicious second wave of coronavirus that is currently ravaging the nation.
Right now, Pfizer colleagues at distribution centers in the U.S., Europe and Asia are hard at work rushing shipments of Pfizer medicines that the Government of India has identified as part of their COVID treatment protocol.
We are donating enough of these medicines to ensure that every COVID-19 patient in every public hospital across India can have access to them in the next 90 days free of charge. This effort has the potential to impact the lives of hundreds of thousands of patients.
These medicines, valued at more than $70M, will be made available immediately, and we will work closely with the government and our NGO partners to get them to where they are needed most.

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Pfizer Inc.

Pfizer Inc. Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @pfizer

9 Apr
BREAKING: Today, with @BioNTech_Group, we submitted a request to US FDA to expand emergency use of our COVID-19 vaccine to adolescents 12 to 15 years of age.
We plan to request similar rulings by other regulatory authorities worldwide in coming days.
Pending regulatory decision, our hope is to make this vaccine available to the 12-15-year-old age group before the start of the 2021 school year.
Read 5 tweets
23 Mar
Today, we announced that we’ve started testing the safety profile of our novel oral #antiviral investigational drug candidate for SARS-CoV-2 infections. #COVID19 #ScienceWillWin
After initial promising preclinical data, we’ve begun dosing healthy adult participants with our novel oral #antiviral investigational drug candidate as part of a Phase 1 #clinicaltrial.
This potential first-in-class SARS-CoV-2 protease inhibitor binds to the virus & may stop the virus from replicating in the body. Protease inhibitors have previously been proven to be effective against other viruses like HIV & hepatitis C.
Read 4 tweets
25 Nov 20
You’ve got questions, we’ve got answers. Angela Hwang, our Group President, Biopharmaceuticals, answers questions on our #COVID19 vaccine candidate.

Kicking off the 🧵, Q: What is the status of the Pfizer and BioNTech investigational COVID-19 vaccine candidate? (1/7)

Q: What happens after the U.S. EUA application is submitted? How does it get authorized for use? (2/7)

Q: If the Pfizer and BioNTech COVID-19 vaccine candidate is authorized for emergency use in the U.S., who will receive it first? (3/7)

Read 7 tweets
18 Nov 20
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.
The study reached 170 confirmed cases of #COVID19, with the #vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose.
Additionally, the safety milestone required by @US_FDA for Emergency Use Authorization (EUA) has been achieved. To date, no serious safety concerns related to the vaccine candidate have been reported.
Read 5 tweets
6 May 20
We are working determinedly to bring forth medical solutions that could bring an end to the #coronavirus pandemic.

Here’s Kathrin Jansen, our Head of Vaccine Research & Development, with answers to some of your biggest questions about a potential #COVID19Vaccine:
Q: What is the thinking behind your #clinicaltrial program for #COVID19?

#KnowTheFacts #FactsOnVaccines
KJ: Researchers and scientists around the world are working to develop a potential vaccine, and different groups are using different methods. At Pfizer, we’re collaborating with @BioNTech_Group to focus on a technology called mRNA.
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!